Abstract Changes in myocardial metabolism, including a shift from fatty acid to glucose utilization and changes in fatty acid availability and composition are characteristics of heart failure development. Tetradecylthioacetic acid (TTA) is a fatty acid analogue lacking the ability to undergo mitochondrial b-oxidation. TTA promotes hepatic proliferation of mitochondria and peroxisomes and also decreases serum triglycerides and cholesterol in animals. We investigated the effect of TTA, in combination with a high-fat or regular diet, in a rat model of post-myocardial infarction heart failure. TTA had a beneficial effect on cardiac function in post-myocardial infarction heart failure without affecting myocardial remodeling. These effects of TTA on myocardial function were accompanied by decreased free fatty acids in plasma, increased myocardial proportion of n-3 polyunsaturated fatty acids (PUFA) and a decreased proportion of n-6 PUFA. Myocardial enzyme gene expression during TTA treatment suggested that the increase in n-3 PUFA could reflect increased n-3 PUFA synthesis and inadequately increased n-3 PUFA b-oxidation. Based on our data, it is unlikely that the changes are secondary to alterations in other tissues as plasma and liver showed an opposite pattern with decreased n-3 PUFA during TTA treatment. The present study suggests that TTA may improve myocardial function in heart failure, potentially involving its ability to decrease the availability of FFA and increase the myocardial proportion of n-3 PUFA.
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Introduction
Chronic heart failure (HF) is an important and increasing cause of cardiovascular and overall mortality in the Western world [9] . The development of HF, e.g. initiated by a myocardial infarction (MI) or hemodynamic overload, is characterized by structural, cellular, and molecular changes, commonly referred to as myocardial remodeling. These changes include ventricular dilation, cardiac hypertrophy, and fibrosis [18] . Important metabolic changes are also characteristic of HF development, including a shift from fatty acid (FA) to glucose utilization [16] . While the increased reliance on glucose is less oxygen demanding and therefore potentially beneficial for the heart, accumulation of lipids may lead to direct cardiotoxicity [16] . However, these issues are far from clear [10, 20] . Thus, it has been suggested that the down-regulation of FA oxidation enzymes and the switch to carbohydrate oxidation observed in end-stage HF is only a late-stage phenomenon [20] . Also, while some FA may be harmful to the myocardium, others such as n-3 polyunsaturated FA (PUFA) have been shown to decrease mortality and admission to hospital for cardiovascular reasons in HF patients [19] . Identification of metabolic disturbances in HF has resulted in widespread interest in myocardial metabolism as a treatment target in this disorder. However, in what way metabolism should be modulated is unclear [10] . Studies indicate that stimulation of cardiac glucose utilization may be more beneficial than the opposite, i.e., aiming to restore the physiological balance between FA and glucose metabolism [10] . However, although inhibition of carnitine palmitoyltransferase (CPT)-1 could seem attractive resulting in downregulation of the FA oxidation within the myocardium [16] , studies on CPT-1 inhibition in HF has been somewhat disappointing. Also, the results of the studies on substrate utilization in HF are diverse.
Tetradecylthioacetic acid (TTA) is a FA analogue where the ability to undergo mitochondrial b-oxidation is blocked by the substitution of a carbon atom with sulphur in the third position of the carbon chain [24] . TTA seems to mediate its effects through both peroxisome proliferatoractivated receptors (PPAR)-dependent and PPAR-independent mechanisms [1] . Within the liver, TTA promotes hepatic proliferation of mitochondria and peroxisomes, associated with effects on hepatic lipid metabolism, involving PPARa-related mechanisms, and TTA seems also to decrease serum triacylglycerol, cholesterol, and free FA (FFA) levels in animal models [2, 3] . However, the effect of TTA on lipid metabolisms within the failing myocardium has not been clarified.
While TTA has been shown to reduce coronary artery stenosis after percutaneous coronary intervention in experimental models [13] , its effect on the myocardium is far from clear. Recently, TTA administration was shown to elevate FA oxidation and decrease ex vivo cardiac efficiency and post-ischemic functional recovery [8] . To further examine the effect of TTA on the myocardium, we studied the in vivo effect of TTA, in combination with high fat or regular diet, on myocardial function and structure in a rat model of post-MI HF, and we related these findings to the effects of TTA on FA metabolism and FA composition.
We found that treatment with TTA improved myocardial function in post-MI HF rats, and suggest that this effects involve the ability of TTA to increase the myocardial proportion of n-3 PUFA.
Methods

Experimental Rat Model of HF and Study Protocol
Male Wistar rats (*270 g) were randomly selected to receive a regular diet (7.5 % fat; soybean oil) or a high fat diet (25 % fat comprised of 23 % lard, and 2 % soybean oil) for 12 days before they were subjected to left coronary artery ligation or sham operation during isoflurane anesthesia (1 % isoflurane in a mixture of one-third O 2 and two-thirds N 2 O) as previously described [23] . Postoperative mortality of the rats with MI was 33 %. Seven days after MI, echocardiography was performed and rats without transmural infarcts were excluded. Rats fed with regular and high fat diets were randomly assigned to a diet supplemented with or without TTA (0.375 %). Thus, there were four MI groups and four sham groups: MI/low fat (n = 10), MI/low fat ? TTA (n = 9), MI/high fat (n = 13), MI/high fat ? TTA (n = 14), sham/low fat (n = 9), sham/low fat ? TTA (n = 9), sham/high fat (n = 10), sham/high fat ? TTA (n = 11). The rats were euthanized 8 weeks after the induction of MI or sham operation. The study was approved by the Norwegian National Animal Research Committee and conforms to the Guide for Care and Use of Laboratory Animals published by the US National Institutes of health (NIH Publication No. 85-23, revised 1996). The animals were housed three per cage and had free access to food and water during the study.
Echocardiography
Echocardiography was performed 7 days after surgery prior to randomization (baseline), and after 7 weeks of treatment (end-point) with the rats sedated with 0.3 ml/ 100 g body wt Hypnorm Ò -Dormicum Ò [2.5 % Hypnorm Ò (VetaPharma; fentanyl 0.315 mg/ml ? fluanisone 10 mg/ ml) ? 25 % Dormicum Ò (Roche; midazolam 5 mg/ml) in water]. Transthoracic echocardiography was performed with a Vivid 7 scanner and a 14-MHz linear array probe (GE Vingmed Ultrasound, Horten, Norway) by a trained specialist (T.E.) who had no knowledge of the study groups. Two-dimensional-directed M-Mode echocardiography was obtained in the parasternal short-axis view at the level of the papillary muscles. The following parameters were calculated as follows: Fractional shortening (%) = [LV end-diastolic diameter (LVEDD)-LV endsystolic diameter (LVESD)/LVEDD)] 9 100; relative wall thickness = posterior wall thickness (PWT) in diastole/LV internal radius (radius = 0.5 9 LVEDD); posterior wall thickening = PWT in systole-PWT in diastole. LV fractional shortening, and not LV ejection fraction (LVEF), has been considered to be the most reliable echocardiographic measure of LV function in rats as LVEF is more difficult to obtain and less accurate in a small animal models like the rat model than in larger animals and in humans because the need for biplane analysis in the long axis view.
Hemodynamic Measurements
Arterial blood pressure, LV end-diastolic pressure (LVEDP), and LV systolic pressure (LVSP) were measured under isoflurane anesthesia using a 2F micromanometertipped catheter (model SPR-407, Millar Instruments, TX) before the rats were euthanized.
Blood Sampling
Blood was collected from the aorta, drawn into chilled glass tubes containing EDTA (1 mg/mL blood), and centrifuged within 20 min at 4°C (2,000 g in 20 min), before plasma was aspirated and stored at -80°C until use.
Tissue Sampling
The rats were euthanized after the blood sampling by excision of the heart. The lungs, hearts, and livers were excised, weighed, snap frozen in liquid nitrogen and stored at -70°C until use.
Measurements of Plasma Lipids
Plasma lipids were measured on the Hitachi 917 system (Roche Diagnostics GmbH, Mannheim, Germany) using the following kits: total cholesterol (Bayer, Tarrytown, NY), free cholesterol (Wako Chemicals, Dalton, OH), HDL cholesterol (HDL-C Plus, Roche Diagnostics GmbH), low-density lipoprotein (LDL) cholesterol (LDL-C Plus, Roche Diagnostics GmbH), triacylglycerol (Bayer), and phospholipids (PAP 150, bioMérieux, Lyon, France).
Measurements of Total FA Levels and Composition in Plasma, Liver, and Heart Lipids were extracted from plasma, hearts and livers using a mixture of chloroform and methanol. The extracts were transesterified using BF 3 -methanol. To remove neutral sterols and non-saponifiable material, extracts of fatty acyl methyl esters were heated in 0.5 M KOH in ethanol-water solution (9:1). Recovered FA were re-esterified using BF 3 -methanol. The methyl esters were quantified by gas chromatography as previously described [21] . Desaturase indices were estimated in the left ventricle and in the liver according to the following: D5 desaturase index (n-3): C20:5n-3/C20:4n-3, D5 desaturase index (n-6): C20:4n-6/ C20:3n-6, D6 desaturase index (n-3): C18:4n-3/C18:3n-3, D6 desaturase index (n-6): C18:3n-6/C18:2n-6.
Activities of Enzymes Involved in Fatty Acid Metabolism
The tissue samples were homogenised. Nuclei and cell debris were removed by centrifugation for 15 min at 7509g in a tabletop centrifuge. CPT-I, including its activity in the absence and presence of 15 lM malonylCoA, and CPT-II activities were measured in the postnuclear fraction, essentially as described by Bremer [5] . The assay for CPT-I contained 20 mM HEPES, 70 mM KCl, 5 mM KCN, 100 lM palmitoyl-CoA, 10 mg BSA/ml, and 180 lg hepatic tissue protein/ml, and pH was adjusted to 7.5. The reaction was started with 200 lM [methyl-
14 C]-Lcarnitine (200 cpm/nmol). When included, malonyl-CoA was added prior to the start of the reaction. Assay conditions for CPT-II were identical, except that BSA was omitted and 0.01 % Triton X-100 was included. Fatty acylCoA oxidase (FAO) activity was determined by the coupled assay described by Small et al. [15] . cleaned up using RNeasy Mini Columns (Qiagen, Hilden, Germany), and stored at -80°C until analysis. cDNA was synthesized using High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). Quantification of gene expression was performed using the ABI Prism 7,500 (Applied Biosystems), Power SYBR Green Master Mix (Applied Biosystems), and sequence-specific PCR primers designed using the Primer Express software, version 3.0 (Applied Biosystems). Primer sequences can be provided on request. Based on their lack of regulation in the relevant tissue, GAPDH was use as the housekeeping gene in the left ventricle and 18S as the housekeeping gene in the liver for normalization of mRNA data.
Statistical Analysis
All the data are presented as means ± SEM. Repeated measures ANOVA was used for statistical analyses of the effect of TTA treatment on cardiac structure and function where we had repeated measurements. For other analyses, univariate ANOVA was used within each diet regime, focusing on the effect of TTA and its interaction with the rat model (i.e. sham or MI). Thus, each model consisted of TTA treatment and rat model separately and the interaction term TTA*rat model. Since we mainly wanted to investigate the effects of TTA, post hoc analysis was only performed for the effect of TTA within the different groups of animals. If significant, the interaction term p value is also reported. For post hoc analysis, we used unpaired t tests adjusted for the number of within groups comparisons. Thus (0.05/2) P \ 0.025 was considered significant. For all other analyses, P \ 0.05 was considered to be statistically significant.
Results
Effect of TTA on Hemodynamics and Cardiac Structure and Function
The effect of TTA with or without a high fat diet on hemodynamics and cardiac structure and function post-MI is summarized in Table 1 and Fig. 1 . Rats receiving TTA showed significantly decreased body weight, mean arterial pressure (MAP), and LVSP in both sham-operated and post-MI HF rats. We found the same pattern in rats receiving regular and high fat diet, although the decrease in MAP and LVSP did not reach statistical significance in the high fat group. There were no interactions between rat model (i.e., sham or MI) and effect of TTA in the regular or high fat diet groups. However, while the LV fractional shortening decreased during the study period in post-MI HF rats receiving vehicle, it increased in TTA treated rats, reaching statistical significance in the high fat group (Fig. 1a) . Moreover, posterior wall thickening, another parameter of LV function, was also significantly increased in the TTA group on high-fat diet as compared with vehicle treated rats (Fig. 1b) . TTA had no statistically significant Table 1 Effect of TTA on heart weights, hemodynamics and liver enzymes
Body weight (g) 402 ± 16 361 ± 11 397 ± 13 343 ± 4* 413 ± 8 367 ± 10* 409 ± 7 365 ± 11*
Lung weight/TL (mg/mm) 36.1 ± 0.7 33.7 ± 0.9 49.2 ± 7.3 45.8 ± 6.9 36.3 ± 0.5 33.4 ± 0.7 57.9 ± 6.5 49.2 ± 5.2
Plasma AST (U/L) 67.9 ± 3.6 94.1 ± 7.9* 73.4 ± 6.1 126.3 ± 20.8 77.4 ± 4.1 86.9 ± 7.3* 77.6 ± 6.2 104.4 ± 18.4
Plasma ALT (U/L) 29.2 ± 1.9 54.6 ± 5.2* 30.9 ± 2.6 79.4 ± 15.5 36.1 ± 1.8 61.1 ± 6.4 36.6 ± 2.1 76.5 ± 14.8
Liver fatty acids (lg/g) 37.7 ± 2.3 36.2 ± 0.9 34.6 ± 1. 
Effects of TTA on Plasma Lipids
When analyzing the effect of TTA on plasma lipids, several significant findings were revealed (Table 2) . First, TTA markedly reduced total cholesterol, primarily reflecting decreased levels of HDL cholesterol and free cholesterol, triglycerides, and phospholipids in both shamoperated and post-MI HF rats, independent of the diet group. However, a significant interaction was noted between total cholesterol and phospholipids and TTA treatment in the normal diet group suggesting a more beneficial effect in sham operated animals. Second, in contrast to the effects on triglycerides and HDL cholesterol, TTA induced no decrease in LDL cholesterol except for a significant decrease in the high-fat post-MI HF group. Third, in the post-MI HF group that received high fat diet, TTA also markedly decreased LDL cholesterol. Finally, circulating FFA levels, which may be an important regulator of myocardial substrate metabolism in HF potentially contributing to myocardial ischemia and dysfunction [10, 20] , were significantly reduced after treatment with TTA with a particularly pronounced effect in post-MI HF rats receiving high fat diet. These TTA-induced changes in lipids and FFA were accompanied by an increase in plasma levels of alanine and aspartate aminotransferase (AST and ALT), that reach statistical significance in the sham-operated groups, potentially suggesting some degree of liver toxicity (Table 1) . In contrast to the effects on lipids and FFA, the TTA-induced changes in glucose levels were rather modest reaching statistical significance in shamoperated rats on high fat diet.
Effects of TTA on Myocardial FA Composition
In addition to the amount of FFA, the composition of FA is also of importance for myocardial function. As shown in Table 3 , TTA induced several changes in FA composition within the non-ischemic LV with, in general, the same pattern in sham-operated and HF rats independent of the diet group. While the amount of total FA was unchanged with a minor increase in sham-operated animals receiving TTA in the high fat diet group, TTA induced a marked decrease in the proportion of saturated FA (SFA), e.g., C14:0, C16:0, and C18:0 (data not shown), with the most pronounced decrease in the post-MI HF rats. In contrast, TTA significantly increased the proportion of n-3 PUFA and decreased the proportion of n-6 PUFA resulting in a marked increase in n-3:n-6 ratio. As for monounsaturated FA (MUFA), no changes were observed.
Differential Effects of TTA on n-3 and n-6 PUFA Levels in the Myocardium Compared with Plasma and Liver During TTA treatment, there was a marked increase in levels of n-3 PUFA and a decrease in n-6 PUFA within the myocardium, and it could be claimed that these changes were secondary to similar changes in other tissue or plasma. However, while TTA induced a marked increase in the proportion of C20:5n-3 (eicosapentaenoic acid, EPA), C22:5n-3 (docosapentaenoic acid, DPA), and C22:6n-3 (docosahexaenoic acid, DHA) within the myocardium, an opposite pattern was seen in plasma and liver in both shamoperated and post-MI HF rats with decreased levels of C20:5n-3, C22:5n-3, and C22:6n-3 with a more pronounced decrease in C20:5n-3 in sham-operated mice receiving high-fat diet (Fig. 2a-c) . Moreover, while the myocardial decrease in n-6 PUFA during TTA treatment primarily reflected a marked decrease C20:4n-6 (arachidonic acid), the TTA-induced decrease in n-6 PUFA in liver, and in some degree also in plasma, reflected a decrease in C18:2n-6 ( Fig. 2d-e) . Thus, although we lack data from skeletal muscles, it seems unlikely that the increase in n-3 PUFA and the decreased n-6 PUFA within the myocardium are secondary to an increase in other tissues.
TTA May Induce Enhanced Synthesis and Impaired
Oxidation of Myocardial n-3 PUFA A major finding so far is the increase in n-3 PUFA within the myocardium as opposed to decreasing levels within the liver following TTA treatment. An increase in myocardial n-3 PUFA could be caused by enhanced up-take within myocardial cells. However, as shown in Fig. 3 , TTA had no influence on the expression CD36 or fatty acid transporter protein-1 (FATP1), both known to promote up-take of long-chain FA in various cells and organs [11] . Notably, however, within the liver, TTA increased the expression of FATP1 and in particular CD36 (Fig. 3 ). An increase in myocardial n-3 PUFA could potentially also reflect increased synthesis within this organ. TTA induced a significantly increased expression in D5 desaturase (fatty acid desaturase 1) in post-HF rats receiving normal diet with a similar TTA-induced pattern for the other conditions (Fig. 4) . Interestingly, within the myocardium, TTA induced an increase in D5 desaturase index for n-3 PUFA, reflecting an increased proportion of C20:5n-3, and a decrease in D5 desaturase index for n-6 PUFA, reflecting a decreased proportion of C20:4n-6, with the same pattern in all conditions. In contrast, no effects on the myocardial expression of D6 desaturase (fatty acid desaturase 2) were observed, although there was an increase in the D6 desaturase index reflecting an increased proportion of C18:3n-6 in all TTA conditions (Fig. 4) . In contrast to the myocardium, TTA induced a marked increase in both D5 and D6 desaturase within the liver, although the D5 desaturase index for n-6 PUFA decreased (Fig. 4) . As for elongase, no TTA-induced changes were seen in either liver or myocardium (data not shown).
Impaired myocardial oxidation of hardly oxidized FA such as n-3 PUFA could also have contributed to the increased myocardial n-3 PUFA levels during TTA treatment, and our data on the regulation of related enzymes are summarized in Figs. 5 and 6. TTA markedly increased FA acyl-CoA oxidase levels (FAO activity and ACOX-1 expression) (Figs. 5a, 6a) , which is the rate-limiting enzyme for peroxisomal b-oxidation of FA. TTA also induced an increase in CPT-II levels, although the increase in CPT-II activity was rather modest and only significant in post-MI HF rats receiving high-fat diet (Figs. 5b, 6b) . On the other hand, CPT-I, thought to be the rate limiting step in FA oxidation, was not increased during TTA treatment (Figs. 5c, 6c) . Notably, TTA induced a decreased sensitivity to malonyl-CoA inhibition of CPT-I suggesting that CPT-1 during TTA treatment is only partly regulated by malonyl-CoA (Fig. 6d) . Moreover, although there was an increase in medium chain acyl CoA dehydrogenase (MCAD), there was no increase in the myocardial level of long chain acyl CoA dehydrogenase (LCAD) levels, and importantly, LCAD, as opposed to MCAD, is involved in n-3 PUFA b-oxidation within the mitochondria (Fig. 5d-e) . Finally, TTA did not induce any increase in the Values are mass% of total fatty acids and are presented as means ± SEM. P-values reported represent a significant interaction between TTA and MI within each diet (i.e. regular or high-fat diet). P-values on the graphs represent *P \ 0.025 versus vehicle myocardial levels of 2,4-dienoyl-CoA reductase 1 (DECR1), another enzyme that is involved in the mitochondrial b-oxidation of n-3 PUFA (Fig. 5f ). In contrast to the lack of changes in the myocardium, TTA markedly increased the expression of CPT-1, DECR-1, and LCAD within the liver (Fig. 5) . Taken together, our data may suggest that the increase in the myocardial levels of n-3 PUFA during TTA intervention could at least partly reflect increased synthesis of n-3 PUFA combined with an inadequate increase in n-3 PUFA b-oxidation (lack of increase in LCAD, CPT-1, and DECR-1), with the same pattern in high-fat and normal diet as well as in sham-operated and MI rats.
The Interaction Between TTA and PPARs Within the Liver and Myocardium Our findings suggest that TTA enhances the myocardial expression of PPARa/PPARd-related genes (e.g., ACOX-1, MCAD, and CPT-II). However, several myocardial target genes of these PPARs were not regulated by TTA (e.g., CPT-I and LCAD), indicating a more complex interaction between TTA and PAARs within the myocardium as compared with the liver. In line with this, while TTA significantly enhanced mRNA levels of PPARa within the liver, no clear-cut effect was seen within the myocardium with a tendency for decreased rather than increased mRNA levels in TTA-treated post-MI HF rats (Fig. 7a) . As for PPARd and PPARc, the effect of TTA on mRNA levels was modest and not significant in both liver and myocardium (Fig. 7b, c) .
Effects of TTA on Mediators Involved in Glucose Metabolism in Non-ischemic LV
As shown in Fig. 8a-b , TTA had no effect on mRNA levels of the glucose transporter type 4 (GLUT4) or citrate synthase, the first step of the citric acid cycle, within the myocardium. In contrast, TTA markedly enhanced the mRNA levels of pyruvate dehydrogenase kinase 4 (PDK4) with the most pronounced response in the shamoperated rats (Fig. 8c) , an enzyme that inhibits the pyruvate dehydrogenase complex by phosphorylating one of its subunits, reducing the conversion of pyruvate to acetyl CoA and thereby, inhibiting the metabolism of glucose. desaturase index (n-3) (C18:4n-3/C18:3n-3), (f) D6 desaturase index (n-6) (C18:3n-6/C18:2n-6). Values are presented as means ± SEM. n = 9-14. P-values reported represent a significant interaction between TTA and MI within each diet (i.e. regular or high-fat diet). P-values on the graphs represent *P \ 0.025 versus vehicle 
Discussion
The novel finding in the present study was that TTA prevents further LV functional deterioration in post-MI HF in rats without affecting the myocardial remodeling process. Thus, TTA improved fractional shortening and increased posterior wall thickening in post-MI HF rats on high-fat diet receiving TTA as opposed to vehicle suggesting beneficial effects of TTA on LV function. Since the beneficial effect of TTA on LV systolic function after MI was not associated with attenuated LV remodeling, it is a possibility that TTA improves cardiac function by improving myocardial metabolism and energetics. Of note, the TTAinduced improvement in myocardial function was accompanied by several changes in lipid profile, including an increased myocardial proportion of n-3 PUFA such as EPA and DHA. Our findings may suggest that the beneficial effects of TTA in post-MI HF could involve its ability to increase the proportion of n-3 PUFA within the LV. While TTA induced a decrease in FFA in plasma, there were only minor changes in levels of total FA within the myocardium. However, in addition to the amount of FA available, the composition of the FA is also of importance for the effect of FA on the myocardium. In the present study, we showed that TTA induced a shift from SFA to PUFA within the myocardium in both sham-operated and HF rats, independent of regular or high fat diet, reflecting an increased proportion of n-3 PUFA. We have recently showed similar effects of long term treatment with TTA and fish oil in healthy rats [17] . Notably, while TTA increased the proportion of C20:5n-3, C22:5n-3, and C22:6n-3 in LV of both sham-operated and post-MI HF rats, an opposite pattern was seen in plasma and in the liver with decreased levels of these n-3 PUFA. Moreover, while TTA induced a significant increase in the myocardial expression of D5 desaturase, but not in D6 desaturase, TTA induced a marked increase in both these desaturases, accompanied by a decrease in n-6 and in particular in n-3 PUFA within the liver. Finally, while TTA showed a rather complex effect on enzymes involved FA oxidation within the myocardium with no effect on CPT-1, LCAD, and DECR1, all involved in n-3 PUFA b-oxidation within the mitochondria, TTA markedly increased the expression of these enzymes within the liver. Our findings clearly show that TTA differently affects n-3 PUFA metabolism in the myocardium and in the liver, and suggest that the enhanced myocardial n-3 PUFA levels during TTA treatment could involve increased synthesis of n-3 PUFA and in particular an inadequate or no increase in n-3 PUFA b-oxidation.
While there was a marked up-regulation of the myocardial levels of FAO/ACOX1 during TTA treatment, representing the rate-limiting enzyme for peroxisomal b-oxidation of FA, the effect of mitochondrial related enzymes involved in b-oxidation of FA was more complex, showing enhancing (i.e., CPT-II, MCAD) or no (i.e., CPT-I, LCAD, DECR-1) effect. In contrast, the hepatic expression of all these mediators was markedly up-regulated during TTA treatment. This suggests that while TTA enhance both peroxisomal and mitochondrial related b-oxidation of FA within the liver, the effect of TTA on mitochondrial b-oxidation within the myocardium is more complex, potentially resulting in attenuated b-oxidation of n-3 PUFA within the myocardium. Our findings may apparently seem in conflict with the study by Hafstad et al. [8] , showing that TTA induced enhanced FA oxidation within the myocardium. However, while we showed decreased or lack of increase in the expression of enzymes known to be related to the oxidation of n-3 PUFA, TTA increased FA acyl-CoA oxidase levels (FAO activity and ACOX-1 expression) and also induced an increase in CPT-II levels, although the increase in CPT-II activity was rather modest. Moreover, while Hafstad et al. [8] studied the effect of in vivo TTA administration in an ex vivo model of myocardial ischemia/reperfusion, we studied the effect of TTA on post-MI HF in vivo. Experimental studies have suggested beneficial effects of n-3 PUFA on the myocardium [6, 12, 19] , and several theories have been put forward to explain these adaptive effects. These include favorable effects on glucose and lipid metabolism, alterations in cardiac membrane lipid composition, effects on sodium channels, direct vasorelaxant action, and improvements in the sodium-potassium ATPase enzyme system [12, 22] . In addition, gene profiling studies have suggested that n-3 PUFA, including EPA and DHA, may down-regulate genes related to cellular pathways controlling inflammatory responses, cardiac remodeling, angiogenesis, and apoptosis [4] . Although we have no firm evidence, it is therefore tempting to hypothesize that the beneficial effects of TTA on myocardial function could involve an increased proportion of n-3 PUFA within the myocardium. While TTA induced a decrease in n-6 PUFA both in the myocardium and in the liver, the regulation of the various n-6 PUFA was different in these organs. Thus, while the decrease in myocardial n-6 PUFA during TTA treatment reflected a marked decrease in C20:4n-6 (arachidonic acid), the decrease in the liver seemed to reflect a marked decrease in C18:2n-6. Arachidonic acid is metabolized by cyclooxygenase, lipoxygenase, and cytochrome P450 to numerous compounds with both harmful, but potentially also protective effects on the myocardium [7] . Thus, while the consequences of the myocardial decrease in arachidonic acid during TTA treatment are unclear, this finding further underscores that TTA differentially affects hepatic and myocardial FA metabolism.
TTA induced increased expression of PDK4 which, by inhibiting the pyruvate dehydrogenase complex, will impair glucose metabolism, suggesting a shift from glucose to FA metabolism within the myocardium. Favor of FA oxidation over glucose metabolism is regarded as more energy consuming with potential harmful effects on the myocardium [10, 20] , which may seem in variance with the improved myocardial function in post-MI HF rats that received TTA. However, although inhibition of PDK activity, inducing a shift from FA to glucose metabolism, has been suggested as a useful therapeutic target for avoiding impaired myocardial function during heart surgery or acute ischemia [14] , the effect of this therapeutic approach on chronic HF is not clear. It is also possible that the potential harmful effect of increased PDK4 levels is counteracted by increased myocardial proportion of n-3 PUFA as discussed above.
The correlative nature of the experiments is a limitation of the present study. Moreover, although correction for multiple comparisons was performed, some of the findings could be by chance. Moreover, for several of the investigated enzymes, we lack protein and activity data. Nonetheless, our data suggest that TTA may improve myocardial function in post-MI HF rats, potentially involving the ability of this modified FA to increase the myocardial proportion of n-3 PUFA. However, the effect of TTA on the myocardium in HF is rather complex, potentially involving adaptive as well as maladaptive effects. The mechanisms for the TTA-mediated improvement in myocardial function in HF are at present not clear and will have to be further investigated in forthcoming studies. Such studies could also give insight into the interaction between glucose and FA metabolism and myocardial remodeling.
